Renal Function in Children with β-Thalassemia Major Treated with Iron Chelating Agent

Olga Rasiyanti Siregar, Rosmayanti Syafriani Siregar, Bidasari Lubis

Abstract


BACKGROUND: Thalassemia is a disorder of inherited blood and inticated by the abnormal hemoglobin. Transfusion and iron chelation are part of thalassemia management. Iron chelating agent reduces complications due to the excess iron as a result of repeated transfusions, hence, increasing the survival rate. However, prolonged intake of iron chelating agent may increase the risk of renal function impairment. To date, evaluation of renal function in children with β-thalassemia in Medan has never been reported. The objective of this study was to evaluate renal function and other factors in children with β-thalassemia.

METHODS: Fourty-five children with β-thalassemia was recruited in this study. Renal function, represented by estimated glomerular filtration rate (eGFR)and serum ferritin levels were examined. The measurement of eGFR was using Schwartz method.

RESULTS: Decreased eGFR observed in some the children (2 patients) with β-thalassemia major treated with iron chelating agent. None of the factors examined had association with serum creatinine level. Children's age and duration of iron chelating agent intake had positive correlation with their eGFR (r=0.506, p<0.001 and r=0.518, p<0.001, respectively). However, serum ferritin levels was not a predictor for renal function impairment.

CONCLUSION: Most of children with β-thalassemia major treated with iron chelating agent have normal renal function, nevertheless, decreased renal function is observed in few children. Highlighted, renal function examinations should be performed routinely as iron chelating agent administration is a long-term therapy in children with β-thalassemia major.

KEYWORDS: β-thalassemia major, renal function, serum ferritin levels, iron chelating agent


Full Text:

PDF

References


Weatherall DJ. The thalassemias: disorders of globin synthesis In: Kaushansky K, Prchal JT, Press OW, Lichtman MA, Levi M, Burns LJ, et al, editors. Williams Hematology. 9th ed. New York: McGraw Hill; 2016. p.726-58, article.

Thalassemia International Federation. Guidelines for The Management of Transfusion Dependent Thalassemia (TDT). 3rd ed. Cyprus: Thalassemia International Federation; 2014, article.

Graziano JH, Grady RW, Cerami A. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug. J Pharmacol Exp Ther. 1974; 190: 570-5, PMID.

Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann NY Acad Sci. 2010; 1202: 1-9, CrossRef.

Halliwell B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic Biol Med. 1989; 7: 645-51, CrossRef.

Perera NJ, Lau NS, Mathews S, Waite C, Ho PJ, Caterson ID. Overview of endocrinopathies associated with β-thalassaemia major. J Intern Med. 2010; 40: 689-96, CrossRef.

Mastrangelo F, Lopez T, Rizzelli S, Manisco G, Corliano O, Alfonso L. Function of the kidney in adult patients with Cooley’s disease A preliminary report. Nephron. 1975; 14: 229-36, CrossRef.

Koren G, Bentur Y, Strong D, Harvey E, Klein J, Baumal R, et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child. 1989; 143: 1077-80, CrossRef.

Cianciulli P, Sorrentino F, Forte L, Palombi M, Papa G, Meloni C, et al. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. Haemotologica. 1992; 77: 514-5, PMID.

Ciaciulli P, Sollecito C, Sorrentino F, Forte L, Gilardi E, Massa A, et al. Early detection of nephrotoxic effects in thalassemic patients receiving desferoxamine therapy. Kidney Int. 1994; 46: 467-70, CrossRef.

Ahmadzadeh A, Jalali A, Assar S, Khalilian H, Zandian K, Pedram M. Renal tubular dysfunction in pediatric patients with betathalassemia major. Saudi J Kidney Dis Transpl. 2011; 22: 497-500, article.

Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkosky JL, et al. Renal dysfunction in patients with thalassemia. Br J Haematol. 2011; 153: 111-7, CrossRef.

Allon M. Renal abnormalities in sickle cell disease. Arch Intern Med. 1990; 150: 501-4, CrossRef.

Lai ME, Spiga A, Vacquer S, Carta MP, Corrias C, Ponticelli C. Renal function in patients with β thalassemia major : a long term follow up study. Nephrol Dial Transplant. 2012; 27: 3547-51, CrossRef.

Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ong-ajyooth S, Sunthornchart S, Pattanakitsakul S, et al. Renal tubular function in beta-thalassemia. Pediatr Nephrol. 1998; 12: 280-3, CrossRef.

Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, et al. Renal dysfunction in patients with β-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematologica. 2010: 123; 148-52, CrossRef.

Smolkin V, Halevy R, Levin C, Mines M, Sakran W, Ilia K, et al. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol. 2008; 23: 1847-51, CrossRef.

Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008; 17: 127-32, CrossRef.




DOI: https://doi.org/10.18585/inabj.v12i3.1053

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute